Canexis Pharma AG (“Canexis”), an emerging Swiss company in the field of pharmaceutical cannabis products, has received from Swissmedic the Manufacturing and narcotics license for cannabis medicines received. These licenses are a significant milestone for Canexis, as they enable the company to produce high-quality CBD and THC-based active pharmaceutical ingredients for the Swiss and international markets.
After four years of intensive preparation and development, production is now starting in the specially designed facility in Schlattingen in the canton of Thurgau. The state-of-the-art building was designed around the production process, aligned with GMP from the start and completed in 2022. It houses the most modern technology in clean rooms covering over 2 square meters, which meet the highest quality requirements. Six months after the systems were commissioned, a successful initial inspection confirmed compliance with all required standards, which led to the issuance of the relevant licenses by Swissmedic in April 000. Canexis has therefore met all requirements for market entry and will supply pharmacies and other pharmaceutical companies with active ingredients in the course of 2024.
Innovative processes and global collaborations
Canexis has made a name for itself through extensive know-how in cannabis extraction and a very high GMP level (“Good Manufacturing Practice”). Accordingly, all processes and systems are specifically designed for the extraction and further processing of cannabis. By optimizing process equipment from European market leaders for its own production and exchanging ideas with leading US cannabis companies, Canexis has integrated extensive experience into the manufacturing process, resulting in a significant competitive advantage in product quality, efficiency and product portfolio.
«In just four years, our team built a pharmaceutical company from the ground up, despite several global challenges. We are pleased to now be able to take a new perspective from the focus of the development and to make an active contribution to the development of the cannabis medicine market,” said Sebastian Zeller, CEO of Canexis.
Custom-made prescription drugs (prescriptions) currently dominate the medical cannabis market. Canexis plans to enrich this market with a range of finished medicines based on pure active ingredients extracted directly from the plant. The Canexis production facility can process up to 1'000 kg of cannabis per day, which results in 100 kg of pure active ingredients per day. This means Canexis is able to cover the daily needs of one to four million patients.